Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038577306> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2038577306 endingPage "934" @default.
- W2038577306 startingPage "928" @default.
- W2038577306 abstract "A novel glycolipid, alpha-L-fucopyranosylceramide, was previously isolated and characterized from metastatic human adenocarcinoma [Watanabe, K., Matsubara, T., & Hakomori, S. (1976) J. Biol. Chem. 251, 2385-2387]. For further investigation of the pathobiological significance of this glycolipid with its specific antibodies, the antigen glycolipid alpha-L-fucopyranosylceramide was chemically synthesized by Königs-Knorr-type condensation of 2,3,4-tri-O-benzyl-alpha-L-fucopyranosyl bromide and a ceramide, followed by removal of benzyl groups by catalytic hydrogenation. alpha-L-Fucopyranosyl-N-palmitoylethanolamine and 2,3,4-tri-O-benzyl-alpha-L-fucopyranosylsphingosine were also synthesized. The antibodies prepared against a synthetic alpha-L-fucopyranosyl-ceramide included in liposome reacted very well with the synthetic as well as the natural alpha-L-fucopyranosylceramide isolated from human adenocarcinoma, but the kinetics of the complement-dependent liposome lysis and the complement fixation pattern with the synthetic fucosylceramide were significantly different from those with the natural fucosylceramide. The natural fucosylceramide showed a much weaker immunogenicity than the synthetic fucosylceramide. The remarkable difference in liposome lysis, complement fixation, and immunogenicity between the synthetic and the natural fucosylceramide must be due to the difference in ceramide structures. The results indicate that the strength of antigenicity and immunogenicity of glycolipids may greatly depend on ceramide structure, whereas the specificity is solely determined by the sugar moiety. The anti-alpha-L-fucosylceramide antibodies display cross-reactivity with galactosylceramide, ceramide, and liposome alone that was eliminated by absorption with galactosylceramide liposomes." @default.
- W2038577306 created "2016-06-24" @default.
- W2038577306 creator A5070398233 @default.
- W2038577306 creator A5075897957 @default.
- W2038577306 creator A5089534983 @default.
- W2038577306 date "1982-03-02" @default.
- W2038577306 modified "2023-09-27" @default.
- W2038577306 title "Chemical synthesis of .alpha.-L-fucopyranosylceramide and its analogs and preparation of antibodies directed to this glycolipid" @default.
- W2038577306 cites W1573760044 @default.
- W2038577306 cites W1588043332 @default.
- W2038577306 cites W1595476916 @default.
- W2038577306 cites W2002308867 @default.
- W2038577306 cites W2022668619 @default.
- W2038577306 cites W2149287717 @default.
- W2038577306 cites W2171793722 @default.
- W2038577306 cites W2302680933 @default.
- W2038577306 cites W2321911292 @default.
- W2038577306 cites W2324806963 @default.
- W2038577306 cites W2460694730 @default.
- W2038577306 doi "https://doi.org/10.1021/bi00534a018" @default.
- W2038577306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7074061" @default.
- W2038577306 hasPublicationYear "1982" @default.
- W2038577306 type Work @default.
- W2038577306 sameAs 2038577306 @default.
- W2038577306 citedByCount "19" @default.
- W2038577306 crossrefType "journal-article" @default.
- W2038577306 hasAuthorship W2038577306A5070398233 @default.
- W2038577306 hasAuthorship W2038577306A5075897957 @default.
- W2038577306 hasAuthorship W2038577306A5089534983 @default.
- W2038577306 hasConcept C147483822 @default.
- W2038577306 hasConcept C159654299 @default.
- W2038577306 hasConcept C185154212 @default.
- W2038577306 hasConcept C185592680 @default.
- W2038577306 hasConcept C190283241 @default.
- W2038577306 hasConcept C203014093 @default.
- W2038577306 hasConcept C22222904 @default.
- W2038577306 hasConcept C2777851122 @default.
- W2038577306 hasConcept C2779026604 @default.
- W2038577306 hasConcept C2780868878 @default.
- W2038577306 hasConcept C55493867 @default.
- W2038577306 hasConcept C71240020 @default.
- W2038577306 hasConcept C86803240 @default.
- W2038577306 hasConceptScore W2038577306C147483822 @default.
- W2038577306 hasConceptScore W2038577306C159654299 @default.
- W2038577306 hasConceptScore W2038577306C185154212 @default.
- W2038577306 hasConceptScore W2038577306C185592680 @default.
- W2038577306 hasConceptScore W2038577306C190283241 @default.
- W2038577306 hasConceptScore W2038577306C203014093 @default.
- W2038577306 hasConceptScore W2038577306C22222904 @default.
- W2038577306 hasConceptScore W2038577306C2777851122 @default.
- W2038577306 hasConceptScore W2038577306C2779026604 @default.
- W2038577306 hasConceptScore W2038577306C2780868878 @default.
- W2038577306 hasConceptScore W2038577306C55493867 @default.
- W2038577306 hasConceptScore W2038577306C71240020 @default.
- W2038577306 hasConceptScore W2038577306C86803240 @default.
- W2038577306 hasIssue "5" @default.
- W2038577306 hasLocation W20385773061 @default.
- W2038577306 hasLocation W20385773062 @default.
- W2038577306 hasOpenAccess W2038577306 @default.
- W2038577306 hasPrimaryLocation W20385773061 @default.
- W2038577306 hasRelatedWork W1480374655 @default.
- W2038577306 hasRelatedWork W1980118001 @default.
- W2038577306 hasRelatedWork W2012509070 @default.
- W2038577306 hasRelatedWork W2053222732 @default.
- W2038577306 hasRelatedWork W2092538248 @default.
- W2038577306 hasRelatedWork W2182347267 @default.
- W2038577306 hasRelatedWork W2400773338 @default.
- W2038577306 hasRelatedWork W2417218348 @default.
- W2038577306 hasRelatedWork W2980942130 @default.
- W2038577306 hasRelatedWork W2189501190 @default.
- W2038577306 hasVolume "21" @default.
- W2038577306 isParatext "false" @default.
- W2038577306 isRetracted "false" @default.
- W2038577306 magId "2038577306" @default.
- W2038577306 workType "article" @default.